Diagnosis and treatment of latent tuberculosis infection
10.5124/jkma.2019.62.1.11
- Author:
Jinsoo MIN
1
;
Ju Sang KIM
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. kimjusang@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Latent tuberculosis;
Antituberculosis agent;
Interferon-gamma release assay;
Tuberculin skin test
- MeSH:
Diagnosis;
Interferon-gamma;
Interferon-gamma Release Tests;
Isoniazid;
Latent Tuberculosis;
Skin Tests;
Tuberculin;
Tuberculosis
- From:Journal of the Korean Medical Association
2019;62(1):11-17
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
In order to eliminate tuberculosis worldwide by 2050, effective management of latent tuberculosis infection is essential, and policy-makers have begun to recognize the importance of scaling up preventive therapy. The current guideline recommends targeted latent tuberculosis infection testing that identifies high-risk groups based on risk stratification for progression from latent infection to active disease. Both the tuberculin skin test and interferon-gamma releasing assay have a similar diagnostic efficacy for predicting progression to active tuberculosis. The Korean guideline recommends 9-month isoniazid monotherapy as the standard treatment; however, more evidence supports that short course rifampicin-based regimen is both more effective and tolerable than isoniazid monotherapy.
